Study of Efficacy and Safety of Twice Daily Oral LNP023 in Adult PNH Patients With Residual Anemia Despite Anti-C5 Antibody Treatment

NCT04558918 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

97

Enrollment

INDUSTRY

Sponsor class

Conditions

Paroxysmal Nocturnal Hemoglobinuria (PNH)

Interventions

DRUG: LNP023
DRUG: Eculizumab
DRUG: Ravulizumab

Sponsor

Novartis Pharmaceuticals